Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENGOT-cx1/BGOG-cx1: Carboplatin + paclitaxel with or without nintedanib in advanced or recurrent cervical carcinoma
2012-004076-19Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Cervical Cancer (CC) comparing Carboplatin + paclitaxel + nintedanib with Carboplatin + paclitaxel + placebo (2 arms). Primary endpoint: Progression-free survival. Started Oct 2013; status: completed.
02
Drugs
nintedanib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2012-004076-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004076-19.